Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 10 Fast-growings companies in Argatroban
by Most Patent Filing In 5 Years in the world in 2022

The Argatroban top 10 is Discovery PatSnap’ annual ranking of the top 10 Most Patent Filing In 5 Years Argatroban Fast-growings in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.
Page generation time: May 07 2025